The Safety, Tolerability, and Pharmacokinetics Profile of BT-11, an Oral, Gut-Restricted Lanthionine Synthetase C-Like 2 Agonist Investigational New Drug for Inflammatory Bowel Disease: A Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Trial
Leber, Andrew, Hontecillas, Raquel, Zoccoli-Rodriguez, Victoria, Colombel, Jean-Frederic, Chauhan, Jyoti, Ehrich, Marion, Farinola, Nicholas, Bassaganya-Riera, JosepLanguage:
english
Journal:
Inflammatory Bowel Diseases
DOI:
10.1093/ibd/izz094
Date:
May, 2019
File:
PDF, 275 KB
english, 2019